| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2123651 | European Journal of Cancer | 2012 | 6 Pages |
Abstract
Preliminary data suggest that pneumonitis may be a marker of stable disease by RECIST and therefore, of therapeutic benefit. Careful patient assessment should be undertaken before the drug is discontinued.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Donnette A. Dabydeen, Jyothi P. Jagannathan, Nikhil Ramaiya, Katherine Krajewski, Fabio A.B. Schutz, Daniel C. Cho, Ivan Pedrosa, Toni K. Choueiri,